Clinical Data, Signs Exclusive License For Monoclonal Antibody Pharmacogenetic Patent Portfolio

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data Inc. (NASDAQ: CLDA) announced today that it has signed an exclusive worldwide license to an extensive portfolio of patents related to a variation in the Fc gamma receptor IIIA gene. Clinical Data’s intent, is to develop a Therapeutic Diagnostic™ for response to rituximab (Rituxan®, Genentech/Biogen-Idec and Mabthera®, Hoffmann-La Roche) in the treatment of non-Hodgkin’s Lymphoma (NHL).

Back to news